Replies to post #144926 on Amarin Corp Plc (AMRN)

[Pyrrhonian]

What’s the CEO’s personal #? I’ll call.

So the fact that two major generics players are currently still vying for entering the market with generic Vascepa in 2020 (or actually isn’t it 2019?), and AMRN’s agreement with Teva not to sell until 2029 is dependent on them NOT making it to market with their products, doesn’t bother you in the least? Those two are currently on a path to come to market. I’m sure they’re only more eager to now.